IZOZF Stock Chart & Stats
$0.17
<$0.01(1.45%)
At close: 4:00 PM EDT
$0.17
<$0.01(1.45%)
Day’s Range― - ―
52-Week Range$0.10 - $0.37
Previous CloseN/A
Volume2.26K
Average Volume (3M)11.59K
Market Cap
$11.21M
Enterprise Value$19.25
Total Cash (Recent Filing)$219.71K
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)―
Beta-0.80
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding69,724,680
10 Day Avg. Volume16,720
30 Day Avg. Volume11,588
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-3.74
Price to Sales (P/S)0.00
P/FCF Ratio-24.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Breast-Imaging ProductA focused product strategy gives Izotropic a clearly defined clinical use case and commercialization target. IzoView is designed specifically for breast imaging, which can help concentrate development, regulatory, and market-entry resources around a distinct diagnostic application over the next several quarters.
Moderating Cash BurnThe substantial reduction in operating cash outflow indicates improved spending discipline compared with the peak-burn years. Although cash flow remains negative, sustaining lower operating outflows could extend available resources and reduce the pace of external funding needs while commercialization efforts continue.
Lower Annual LossesAnnual losses remain substantial, but they are below the peak levels reported in 2022 and 2023. This improvement suggests some expense control and a potentially more disciplined operating structure, which could support longer-term execution if the company converts its product development into commercial revenue.
Bears Say
No Reported RevenueThe absence of reported revenue across six years shows that the business has not yet established commercial traction or demonstrated product-market monetization. Continued pre-revenue operations leave future performance dependent on successfully commercializing IzoView and converting development activity into customer-funded growth.
Negative Equity And Rising DebtNegative equity, rising debt, and a very small asset base indicate limited balance-sheet flexibility. This structure increases financing risk and may constrain the company’s ability to fund product development, regulatory work, and commercialization without continued access to external capital.
Persistent Negative Free Cash FlowPersistent negative operating and free cash flow means the company is consuming cash rather than funding operations internally. The recent deterioration in free cash flow, combined with ongoing losses and no revenue, reinforces dependence on external financing and increases execution pressure over the medium term.
Izotropic News
IZOZF FAQ
What was Izotropic Corp.’s price range in the past 12 months?
Izotropic Corp. lowest stock price was $0.10 and its highest was $0.37 in the past 12 months.
What is Izotropic Corp.’s market cap?
Izotropic Corp.’s market cap is $11.21M.
When is Izotropic Corp.’s upcoming earnings report date?
Izotropic Corp.’s upcoming earnings report date is Sep 30, 2026 which is in 10 days.
How were Izotropic Corp.’s earnings last quarter?
Izotropic Corp. released its earnings results on Mar 27, 2026. The company reported -$0.003 earnings per share for the quarter.
Is Izotropic Corp. overvalued?
According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued.
Does Izotropic Corp. pay dividends?
Izotropic Corp. does not currently pay dividends.
What is Izotropic Corp.’s EPS estimate?
Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Izotropic Corp. have?
Izotropic Corp. has 69,724,680 shares outstanding.
What happened to Izotropic Corp.’s price movement after its last earnings report?
Izotropic Corp. reported an EPS of -$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Izotropic Corp.?
Currently, no hedge funds are holding shares in IZOZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Izotropic Corp.
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imaging platform, both specifically designed to enable earlier detection and more accurate diagnosis of the disease. Established in 2016, the company maintains its corporate base in Surrey, Canada.
Technical Analysis
Spectral Medical
―
BioMark Diagnostics
―
Perimeter Medical Imaging AI
―
Sona Nanotech Inc
―
VentriPoint Diagnostics
―